Literature DB >> 1639656

Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil: effects on cell survival, DNA repair, and cell recovery.

L L Hughes1, J Luengas, T A Rich, D Murray.   

Abstract

Although 5-fluorouracil (5-FU) is commonly used in conjunction with radiotherapy to treat gastrointestinal malignancies, the molecular mechanisms underlying the clinically observed therapeutic advantage of this combination of agents have not been clearly established. The present in vitro studies addressed the possibility that the radiosensitization of log-phase cultured human colon adenocarcinoma cells by postirradiation administration of 5-FU was accompanied by an interference either with the rejoining of radiation-induced DNA double-strand breaks (DSB's) or with recovery from potentially lethal damage (PLD). Significantly more killing was observed in cells exposed to gamma-rays (1-6 Gy) and then treated with 5-FU (100 micrograms/mL; 0.77 mM) for 1 hr at 37 degrees C than in cells given gamma-rays but not 5-FU; essentially, the survival curve shoulder was removed. DSB rejoining measured using the neutral filter elution method after exposure to 25 Gy was identical regardless of whether 5-FU (100 micrograms/mL) was present during the repair period; thus, radiosensitization by this high-concentration postirradiation 5-FU protocol does not appear to be a result of interference with the overall rate of ligation of gamma-ray-induced DSB's. The effect of 5-FU on the ability of log-phase cells to recover from that sector of PLD that can be expressed by postirradiation incubation with hypertonic (0.5 M) salt solution (HSS) was also examined. When irradiated cells were treated with 5-FU during their recovery period and then incubated with HSS, no clonogenic cells survived. Therefore, although it was not possible to assess the actual kinetics of recovery from gamma-ray-induced PLD in 5-FU-treated cells, the drug clearly altered the metabolism or structure of the cells such that their susceptibility to HSS was markedly enhanced.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639656     DOI: 10.1016/0360-3016(92)90903-u

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice.

Authors:  Chia-Yuan Liu; Hui-Fen Liao; Tsang-En Wang; Shee-Chan Lin; Shou-Chuan Shih; Wen-Hsuing Chang; Yuh-Cheng Yang; Ching-Chung Lin; Yu-Jen Chen
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

2.  Influence of 5-fluorouracil-loaded microsphere formulation on efficient rat glioma radiosensitization.

Authors:  Valérie-Gaëlle Roullin; Martine Mege; Laurent Lemaire; Jean-Pierre Cueyssac; Marie-Claire Venier-Julienne; Philippe Menei; Erik Gamelin; Jean-Pierre Benoit
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

3.  Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

Authors:  H Sayar; Z Shen; S J Lee; M Royce; I Rabinowitz; F Lee; H Smith; S Eberhardt; A Maestas; H Lu; C Verschraegen
Journal:  Invest New Drugs       Date:  2008-09-05       Impact factor: 3.850

4.  Concurrent hypofractionated radiotherapy and 5-Fluorouracil for advanced sarcomas of the bone.

Authors:  C Zambatis; J Skarlatos; M Koukourakis; L Kosma; A Giatromanolaki; K Beroukas; D Yannakakis
Journal:  Sarcoma       Date:  1998

5.  Methoxyamine Enhances 5-Fluorouracil-Induced Radiosensitization in Colon Cancer Cell Line HT29.

Authors:  Samideh Khoei; Roghayeh Poorabdollahi; Ahmad Mostaar; Fariborz Faeghi
Journal:  Cell J       Date:  2017-02-22       Impact factor: 2.479

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.